Key Points
- Artivion SVP Andrew Green sold 6,510 shares at an average price of $27.27, totaling $177,527.70. His remaining stake fell 10.91% to 53,133 shares.
- Artivion shares opened at $25.59, near the lower end of their 52-week range, while the company reported quarterly revenue of $125.76 million, exceeding analysts’ $119.99 million estimate.
- Institutional investors own 86.37% of the stock, and analysts maintain a broadly positive outlook, with a “Moderate Buy” consensus and an average price target of $44.83.
Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Andrew Green sold 1,493 shares of Artivion stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $26.02, for a total value of $38,847.86. Following the sale, the senior vice president directly owned 51,640 shares of the company's stock, valued at $1,343,672.80. This represents a 2.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Artivion Trading Down 0.1%
AORT stock opened at $25.59 on Friday. Artivion, Inc. has a 52 week low of $19.16 and a 52 week high of $48.25. The company has a market capitalization of $1.25 billion, a PE ratio of -365.52 and a beta of 1.25. The company's 50-day simple moving average is $26.09 and its 200 day simple moving average is $29.21. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47.
Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The business had revenue of $125.76 million during the quarter, compared to analysts' expectations of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. As a group, sell-side analysts anticipate that Artivion, Inc. will post 0.45 earnings per share for the current year.
Institutional Trading of Artivion
Large investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd acquired a new position in Artivion during the third quarter worth about $27,000. Rockefeller Capital Management L.P. grew its holdings in shares of Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock valued at $30,000 after purchasing an additional 399 shares during the last quarter. Larson Financial Group LLC increased its position in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company's stock worth $43,000 after purchasing an additional 563 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after purchasing an additional 538 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in Artivion in the 4th quarter valued at approximately $79,000. 86.37% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on AORT shares. Citizens Jmp cut their price target on Artivion from $53.00 to $48.00 and set a "market outperform" rating for the company in a research note on Friday, May 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $44.00 price objective on shares of Artivion in a report on Monday, July 20th. Weiss Ratings downgraded Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Stifel Nicolaus set a $45.00 price target on Artivion in a research report on Monday, June 1st. Finally, Canaccord Genuity Group boosted their price target on Artivion from $39.00 to $40.00 and gave the company a "buy" rating in a research note on Tuesday, August 18th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $44.83.
Read Our Latest Report on AORT
About Artivion
(
Get Free Report)
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
